Concurrent Immunotherapy

MATTERHORN & SPOTLIGHT: Precision Medicine Redefining the Gastric Cancer Paradigm In a nutshell: The “one-size-fits-all” FLOT era is evolving. With the MATTERHORN trial maturing and zolbetuximab entering the UK market, we are witnessing a shift toward biomarker-driven strategies in both the perioperative and metastatic settings.